Re: Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5 year olds in New Zealand, Oster P, O'Hallahan J, Aaberge I, Tilman S, Ypma E, Martin D. Vaccine 2007;25(16):3075-9.
Lennon
Diana
D
D000907:Antibodies, Bacterial / Q000097:blood*; D016667:Bacterial Capsules; D002648:Child; D002675:Child, Preschool; D006801:Humans; D007223:Infant; D008589:Meningococcal Infections / Q000276:immunology / Q000517:prevention & control; D022401:Meningococcal Vaccines / Q000008:administration & dosage / Q000009:adverse effects* / Q000276:immunology*; D038541:Neisseria meningitidis, Serogroup B / Q000276:immunology*; D009520:New Zealand; D011135:Polysaccharides, Bacterial / Q000276:immunology; D013045:Species Specificity
D000907:Antibodies, Bacterial; D022401:Meningococcal Vaccines; D011135:Polysaccharides, Bacterial; C039455:capsular polysaccharide, meningococcal group B